Under a tenth of individuals eligible to benefit from obesity jabs including Wegovy have access to them, states the WHO as it issues its first guidance on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging broader and more equitable access to these injectable treatments.
Based on estimates, more than two billion are projected to be living with obesity by 2030 if no action is taken.
"Our new guidance acknowledges that excess weight is a chronic disease that can be treated with thorough and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are major obstacles to widespread availability to the treatments that can aid individuals in losing significant body mass, explains the agency.
Skinny Jab Supply Crisis
Even under the present most optimistic outlook, the manufacturing of these medications could only cover about 100 million people – less than 10% of eligible patients, according to the health organization.
The guideline calls on governments and firms to expand access, via measures like licensing agreements.
Exclusive production rights on the active ingredient – the primary component of the drug Wegovy – is due to expire in several nations in 2026.
The Way Obesity Injections Function
The injections replicate a body's own hormone to reduce digestion speed, reduce hunger and boost satiety so individuals eat less.
Patients usually begin shedding pounds within a few weeks of starting on the weekly injections.
Evidence points to patients may see weight return after a year of discontinuing the drug, because their normal hunger come back.
To be overweight or obese increases your likelihood for experiencing diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight affects individuals in all nations and was responsible for 3.7 million deaths worldwide in 2024, per the WHO.
